Aptabio Therapeutics Inc. has identified new pyrazole derivatives acting as reactive oxygen species (ROS) production inhibitors reported to be useful for the treatment of cancer, neurodegeneration, fibrosis, liver diseases and dermatological, eye and inflammatory disorders, among other disorders.